Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
NCT ID NCT07038447
First seen Jan 06, 2026 · Last updated Jun 09, 2026 · Updated 26 times
Summary
This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions will receive the therapy to see if it is safe and can reduce disease activity. The goal is to find the right dose and measure improvements in symptoms over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Concord Repatriation General Hospital
Sydney, New South Wales, 2139, Australia
-
Jewish General Hospital
Montreal, H3T1E2, Canada
-
St Vincent's Hospital
Fitzroy, Victoria, 3065, Australia
-
Stanford University
Stanford, California, 94305, United States
-
The Ottawa Hospital, General Campus
Ottawa, K1H 8L6, Canada
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.